Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2â advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
Fasching, P.A., Delea, T., Lu, Y-S., DeBoer, R., Hurvitz, S.A., Moynahan, A., Chandiwana, D., Lanoue, B., Hu, H., Thuerigen, A., O'Shaughnessy, J.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.432
Date:
September, 2020
File:
PDF, 94 KB
2020